The novel new vaccine, which involves injecting weakened malarial-inducing parasites into patients in order to elicit a degree of immunity, has been having successful results. The U.S. biotech company, Sanaria, hopes for continued success in order to alleviate the impact of the widespread disease.
Don’t forget you can visit MyAlerts to manage your alerts at any time.